Skip to Main Content
Article

Patent Transactions and Sovereign Immunity: Where the Two Intersect

12.01.2017

1 minute read

Patent Transactions and Sovereign Immunity: Where the Two Intersect

Steve Blonder, principal in the firm's Commercial Litigation practice group, authored an article for Health Care Law Monthly that discusses how pharmaceutical giant Allergan pioneered a unique transactional strategy, since adopted by companies in other industries, of assigning patent rights to entities with sovereign immunity, such as Native American tribes, in an attempt to shield certain patents from invalidation.

Reprinted from Health Care Law Monthly (Issue 12, Volume 2017) with permission. Copyright ©2017 Matthew Bender & Company, Inc., a member of the LexisNexis® Group. All rights reserved.